A step-by-step guide to structuring a drug launch roadmap that aligns medical affairs, marketing, and market access from day one.
Executive Summary (TL;DR)
The Planning Gap: Most drug launch failures are not scientific — they are structural. Teams begin commercialisation planning too late, after regulatory submission is already underway.
The Alignment Imperative: A launch roadmap that works is not a marketing calendar. It is a cross-functional commitment that synchronises medical affairs, market access, regulatory, and field force readiness around a single commercial timeline.
The Execution Edge: Pharmaceutical companies that begin pre-DCGI launch planning 18–24 months ahead of approval consistently outperform those that start at submission — on both first-year revenue attainment and HCP adoption rates.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. A pharma product launch that survives the market is built on pre-approval alignment — not post-approval improvisation.
Every pharmaceutical product launch begins with a plan. The problem is that most of those plans are built for a world that runs on schedule — and drug development never does. DCGI timelines shift. Market access negotiations extend. A competitor files an unexpected supplementary indication. The plan, designed for a straight line, meets a market that operates in curves.
The solution is not a more detailed plan. It is a more resilient one — a drug launch roadmap structured not around the best-case scenario, but around the critical decision points that determine whether a product reaches its commercial potential in the first 12 months or spends two years recovering from a misaligned launch. This guide lays out exactly how to build that roadmap.
The failure modes of a pharmaceutical product launch are remarkably consistent. Analysis of branded drug launches across Asia-Pacific markets shows that more than 60% of products that underperformed their forecast in year one had begun structured commercial planning less than 12 months before regulatory approval. The roadmap existed — but it was built too late, with too little cross-functional input, and around an assumption that approval would unlock everything simultaneously.
What typically breaks first is the dependency chain. Medical Affairs has not yet completed the scientific platform that informs promotional messaging. Market access has not mapped formulary pathways for the target patient population. The field force has not been trained on the product’s differentiated clinical profile. Each workstream assumed another would be ready first. None of them were.
The architecture of a drug launch roadmap must therefore begin not at approval, but at regulatory submission — or earlier. The pre-DCGI window is where launch readiness is built or lost.
The 18 to 24 months between the decision to file a regulatory submission and the anticipated approval date represent the most strategically valuable and operationally underused phase in pharmaceutical commercialisation. In this window, the product cannot be promoted. Its label is not final. The price is not set. And yet every commercial decision made in this period determines the trajectory of the launch.
During the pre-DCGI planning phase, three workstreams must run in parallel. First, Scientific Platform Development — the foundational clinical narrative that defines how the product’s efficacy and safety data will be translated into messages that resonate with target prescribers, payers, and patients. This platform is not a set of promotional claims. It is the evidence architecture from which all downstream communications — from KOL briefing documents to HCP detail aids — are derived.
Second, Disease Area Shaping must begin before the product name appears in any communication. Unbranded education that addresses the unmet need your product will fill — the treatment gap, the burden of inadequately managed disease, the limitations of current standard of care — prepares the prescribing community to receive a new therapeutic option with genuine clinical context. Third, payer landscape mapping must identify formulary decision-makers, reimbursement timelines, and HEOR data requirements well before submission, so that market access submissions run in parallel with — not behind — the regulatory review.
"Pharmaceutical brands that begin payer engagement before regulatory submission are 2.3× more likely to secure formulary listing within six months of approval — converting regulatory momentum into commercial velocity from day one."
A drug launch roadmap is only as strong as the team accountable for executing it. The most common structural error in pharmaceutical launches is treating the launch team as a subset of the marketing function. In reality, a launch-ready cross-functional launch team must include Medical Affairs, Regulatory, Market Access, Commercial, Digital, and Patient Services — each with defined deliverables, decision rights, and a shared timeline.
The Launch Steering Committee should be established no later than 24 months before target approval. This body is not an update meeting. It is a decision-making forum with authority to resolve the cross-functional conflicts that every launch will generate: when to shift resources from pre-approval market shaping to post-approval promotional deployment; how to prioritise formulary tier negotiations against field force rollout; what to do when a competitor launches two weeks before your approval date.
The Brand Launch Playbook — the master document that integrates all workstreams — must be a living operational tool, not a static slide deck. It should specify the exact triggers for each phase transition: the regulatory milestone that activates the commercial readiness review, the approval date that releases the promotional campaign, the first-week sales data threshold that determines whether field force deployment needs to be accelerated. Ambiguity in the playbook translates directly into lost launch momentum in the market.
A drug launch roadmap without explicit milestones is a narrative, not a plan. Five specific commercialisation milestones should anchor the structure of every roadmap, regardless of therapy area, molecule type, or market.
The pharmaceutical field force is the last point of translation between a product’s clinical data and a physician’s prescribing decision. Yet field force readiness is consistently the workstream that receives the least structured preparation time in the launch roadmap — and the one that generates the most post-launch regret.
Field force readiness is not a training event. It is a capability-building programme that must begin at least 12 months before the anticipated launch date. By Month 6 before approval, every Medical Science Liaison and Key Account Manager should have completed a disease area immersion programme that covers the full clinical trial data, the competitive landscape, the patient identification pathway, and the objection handling framework specific to their call plan.
The deployment model also requires pre-launch structuring. Which HCP segment receives first-wave detailing — and in what geography? What digital touchpoints supplement face-to-face MSL interactions in Tier 2 and Tier 3 cities? How does the CRM capture real-time field intelligence on early prescriber response, and who reviews that data weekly? These operational details determine whether the field force converts the approval momentum into sustained prescribing behaviour — or spends the first quarter delivering a message that is consistent in name only.
A pharma product launch roadmap that survives first contact with the market is built on one foundational principle: every function that will matter on launch day must be engaged, funded, and accountable before regulatory approval is granted. The market does not wait for internal alignment.
The roadmap described here is not a guarantee of launch success. No roadmap is. But it is a structural framework that converts cross-functional intention into coordinated execution — and in pharmaceutical launches, the distance between those two things is precisely where market share is won or lost. The organisations that invest in building this infrastructure before they need it are the ones that lead the market when it matters most.
OneAlphaMed’s Brand Strategy & Product Launch practice supports pharmaceutical companies at every stage of this roadmap, from pre-DCGI planning through 90-day post-launch performance reviews. Learn more at onealphamed.com/brand-strategy-product-launch/
A pharma product launch roadmap is a structured, cross-functional plan that coordinates all commercial, medical, regulatory, and market access activities from pre-submission through post-launch performance review. Unlike a marketing plan, a launch roadmap defines decision triggers, milestone accountabilities, and escalation protocols across all functions involved in bringing a new drug to market.
Best practice is to begin structured commercial planning 18 to 24 months before anticipated DCGI approval. This window allows sufficient time to develop the scientific platform, begin unbranded disease education, file payer dossiers, and complete field force training before the approval date activates the promotional campaign.
A comprehensive launch readiness checklist should cover: scientific platform finalisation, Medical Legal Review clearance for all promotional materials, payer dossier submission, HCP segmentation and targeting, field force training completion, digital infrastructure activation, supply chain confirmation, and patient support programme readiness. The checklist should be audited formally at six months before launch, with escalation protocols for any workstream that fails the readiness threshold.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
